News and Announcements
Proteomics International Advances Deals with Singapore and China Partners
- Published March 21, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Proteomics International Laboratories Ltd (ASX:PIQ) (PILL), the leader in predictive diagnostics for diabetic kidney disease, will advance deals with commercialisation partners in Singapore and China, which is patented in both countries, to the Asian market.
KEY TAKEAWAYS:
- PromarkerD technology has been validated by the peer-reviewed scientific journal EuPA Open Proteomics, the official journal of the European Proteomics Association (EuPA).
- Kidney disease is one of the major complications of diabetes and affects approximately one-third of all adult diabetics. Keeping people alive on dialysis costs more than $100,000 per person per year.
- Globally the diabetes epidemic cost health systems $673 billion dollars in 2015.
- Today there are 231 million people living with diabetes in Asia alone, according to the International Diabetes Federation.
- Worldwide this number is forecast to rise to 642 million people by 2040, and
- 214 million people are predicted to get chronic kidney disease as a result.
Frost & Sullivan states that novel tools like PromarkerD can allow “enhanced management of obesity, diabetes and related complications in the near future”. “If we can stem this health crisis tsunami by identifying and treating people before they are symptomatic we are saving lives, as well as billions of dollars in health costs,” said Dr Lipscombe.
PILL’s diagnostic research is made possible by the company’s proprietary biomarker discovery platform termed Promarker, which searches for protein ‘fingerprints’ in a sample. This disruptive technology can identify proteins that distinguish between people who have a disease and people who do not, using only a simple blood test. It is a powerful alternative to genetic testing.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
